COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

By Pass Surgery With Stem Cell Therapy in Chronic Ischemic Cardiopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00690209
Recruitment Status : Completed
First Posted : June 4, 2008
Last Update Posted : July 8, 2014
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand

Brief Summary:

Surgical revascularization has proven its efficacy in term of morbidity and mortality in patients with multivessel coronary disease and poor left ventricular function. Nevertheless, if left ventricle is severely dilated, the improvement of global contractility and reduction of volumes is frequently absent after CABG even if substantial amount of myocardial viability is present. A value of > 140 ml for end systolic volume has been proposed as the cut off for the absence of recovery after revascularization.

Recently, a reduction of cardiac volumes and improvement of regional and global contractility has been demonstrated in patients with advanced ischemic heart disease, severe dilation of left ventricle and poor candidates for revascularization after injection of stem cells in territories with residual viability.

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Procedure: Autologous bone marrow derived stem cells myocardial transplantation Phase 2

Detailed Description:

The screening of patients will be performed after contrast coronar ventriculography realized for diagnostic or prognostic purpose.

Subsequently all patients will be evaluated by cardiac ce-MR and PET imaging for verification of inclusion criteria.

Patients will be allocated in a single blind manner to one of two therapeutic arms: surgical revascularization alone or surgical revascularization associated with autologous bone marrow derived stem cells injection in viable territories.

During the follow up evolution of left ventricular volumes and contractility will be analyzed by ce-MR and PET imaging at 1 year. Additionally patients' functional status will be assessed by metabolic stress tests and quality of life questionnaire at 6 months, 1 year and 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Official Title: Efficacy of Surgical Coronary Revascularization Associated With Stem Cells Injection in Patients With Severe Chronic Ischemic Heart Disease With Residual Viability. A Prospective, Controlled Pilot Trial.
Study Start Date : May 2008
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Evolution of left ventricular volumes and contractility Evolution of left ventricular volumes and contractility

Secondary Outcome Measures :
  1. Functional status

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic ischemic heart disease
  • Left ventricular dilation (end systolic volume >140 ml)
  • Poor global contractile function (ejection fraction <40%)
  • Substantial amount of residual viability (>30% of left ventricle)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00690209

Layout table for location information
Departements of CardiacSurgery, Cardiology and Radiology
Clermont-Ferrand, France
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Layout table for investigator information
Principal Investigator: Janusz Lipiecki, Dr University Hospital, Clermont-Ferrand
Layout table for additonal information
Responsible Party: University Hospital, Clermont-Ferrand Identifier: NCT00690209    
Other Study ID Numbers: CHU-0034
First Posted: June 4, 2008    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Keywords provided by University Hospital, Clermont-Ferrand:
Chronic ischemic cardiomyopathy with residual viability
surgical coronary revascularization
stem cell therapy
Chronic ischemic heart disease
severe impairment of global contractility left ventricular dilation
residual viability
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Pathologic Processes
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases